Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
To date no targeted agents are available to treat TNBC. Therefore chemotherapy is the only
treatment option. TNBC often has a high amount of tumour infiltrating lymphocytes.
Stimulating the immune cells of TNBC might therefore be an option for these patients to
increase the pathological complete response. pCR is highly correlated with outcome in TNBC.
Therefore the addition of a checkpoint inhibitor in addition to chemotherapy might be an
additional option for these patients.